Holen Sie sich die Stockscreener-App
157.70
1.32%
-2.11
Handel nachbörslich:
158.40
0.70
+0.44%
Schlusskurs vom Vortag:
$159.81
Offen:
$159.85
24-Stunden-Volumen:
1.20M
Relative Volume:
0.84
Marktkapitalisierung:
$21.53B
Einnahmen:
$1.53B
Nettoeinkommen (Verlust:
$-214.69M
KGV:
-89.60
EPS:
-1.76
Netto-Cashflow:
$-43.68M
1W Leistung:
+14.17%
1M Leistung:
-1.70%
6M Leistung:
-7.63%
1J Leistung:
+32.50%
1-Tages-Spanne:
$155.27
$161.38
1-Wochen-Bereich:
$136.21
$165.09
52-Wochen-Spanne:
$110.57
$183.00
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Vergleichen Sie NTRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
157.70 | 21.55B | 1.53B | -214.69M | -43.68M | -1.76 |
|
TMO
Thermo Fisher Scientific Inc
|
484.79 | 180.28B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
209.14 | 147.31B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
663.92 | 52.18B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
120.29 | 33.33B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
190.23 | 31.60B | 15.50B | 1.33B | 2.16B | 7.34 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
1 ‘Strong Buy’ Stock Analysts Think Will Soar 62% - Yahoo Finance
Natera (NTRA) Is Up 14.1% After Raising Revenue Guidance and Launching New Prenatal Test – Has the Bull Case Changed? - simplywall.st
Natera Insider Sold Shares Worth $958,059, According to a Recent SEC Filing - MarketScreener
Natera director Sheena Jonathan sells $958k in NTRA stock - Investing.com
Natera Inc. Reports Strong Growth and Strategic Advances - TipRanks
Natera at Canaccord Conference: Growth and Innovation in Focus - Investing.com
Natera at Canaccord Conference: Growth and Innovation in Focus By Investing.com - Investing.com Australia
New noninvasive prenatal test can screen for CF, other genetic diseases - Cystic Fibrosis News Today
Natera’s Strong Growth Potential and Market Leadership Justify Buy Rating - TipRanks
NTRA Q2 Deep Dive: Oncology Growth, Product Innovation, and Margin Pressures - TradingView
Natera Surges 3.35% as Daily Volume Slumps 49.12% to 310M Dollar Ranking 335th in Market Activity - AInvest
Natera Stock Jumps 13.69% In 3 Days As Technicals Signal Bullish Reversal - AInvest
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cytek Biosciences (CTKB), Natera (NTRA) and Warby Parker (WRBY) - The Globe and Mail
Natera And 2 Other Stocks That May Be Priced Below Their Estimated Value - Yahoo Finance
Mixed Analyst Opinions on Healthcare Stocks Cytek Biosciences, Natera, and Warby Parker - AInvest
Natera introduces prenatal test for detecting inherited conditions - MSN
Natera price target raised to $195 from $185 at Morgan Stanley - TipRanks
Natera raises revenue guidance to $2.1B and targets margin expansion through AI-driven efficiencies - MSN
Evercore Gives Natera (NTRA) Outperform Rating - MSN
Natera's Signatera test to be covered under Medicare - MSN
How much upside does Natera Inc. haveAnalyst Upgrade Watch - thegnnews.com
What is the Moat Score of Natera Inc.Free Growth Stock Screener - mustnews.co.kr
Natera Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Natera, Inc. (NASDAQ:NTRA) Q2 2025 Earnings Call Transcript - Insider Monkey
What technical models suggest about Natera Inc.’s comebackFree Secure Capital Picks With Upside Potential - Newser
14 Best Aggressive Growth Stocks to Buy According to Analysts - Insider Monkey
Natera shares surge 17% after strong Q2 results and upgraded guidance - Invezz
Natera Stock: Growth or Bubble? - StocksToTrade
Natera Inc. Stocks Soar After Impressive Q2 Results - timothysykes.com
Natera’s Stock Leaps Amid Clinical Trial Success - StocksToTrade
Natera (NTRA) Shares Surge on Q2 Outperformance: Is This a Sustainable Growth Story or a Short-Term Overreaction? - AInvest
Natera price target raised to $200 from $194 at Baird - TipRanks
Why Are Natera (NTRA) Shares Soaring Today - Yahoo Finance
Natera Gets First Nod for $8.25 Million Prenatal Test Settlement - Bloomberg Law News
Natera (NTRA) Is Up 5.6% After Raising Revenue Outlook and Launching New Prenatal Test - simplywall.st
Natera’s Latest Achievements Elevate Prospects Post-World Transplant Congress - timothysykes.com
Natera Stock (NTRA) Soars 14% on Strong Financial Results - TipRanks
Natera’s Strong Growth and Strategic Advancements Justify Buy Rating - TipRanks
Natera 2025 Q2 Earnings Deepened Losses Amid Revenue Surge - AInvest
Natera stock price target raised to $255 from $251 at RBC Capital - Investing.com Canada
Bernstein SocGen raises Natera stock price target to $205 on strong revenue - Investing.com
Natera, Inc. shares rise 15.18% premarket after reporting a 32.2% revenue increase in Q2 and raising 2025 outlook. - AInvest
RBC Raises Price Target on Natera to $255 From $251, Keeps Outperform Rating - MarketScreener
Natera price target raised to $200 from $195 at BTIG - TipRanks
Natera's Q2 2025: Unraveling Contradictions in Signatera Growth, Women's Health Impact, and Japanese ASP Aspirations - AInvest
Natera stock price target raised to $215 from $200 at TD Cowen - Investing.com Canada
Earnings call transcript: Natera Q2 2025 sees revenue beat, stock surges - Investing.com UK
Natera's Genetic Gambit: Pioneering the Future of Prenatal Diagnostics Through Innovation and Market Expansion - AInvest
Natera Stock Soars 13.4% on 32.2% Revenue Surge - AInvest
Natera (NASDAQ:NTRA) Delivers Strong Q2 Numbers, Stock Jumps 12.6% - Yahoo Finance
Natera Q2 2025 slides: 32% revenue growth drives raised guidance, stock surges - Investing.com Canada
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Natera Inc-Aktie (NTRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sheena Jonathan | CO-FOUNDER |
Aug 11 '25 |
Sale |
153.67 |
3,000 |
461,012 |
34,282 |
| Chapman Steven Leonard | CEO AND PRESIDENT |
Aug 01 '25 |
Sale |
132.88 |
5,807 |
771,656 |
163,593 |
| Marcus Gail Boxer | Director |
Aug 01 '25 |
Sale |
133.17 |
2,496 |
332,395 |
5,763 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
Aug 01 '25 |
Sale |
132.89 |
3,000 |
398,657 |
123,059 |
1.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):